
novel potent ATP-competitive, AKT inhibitor with an IC50 of 6 in vitro and in vivo and induces marked antitumor responses. activity and inhibited the phosphorylation of a range of in vitro, consistent with AKT inhibition. CCT128930 caused human glioblastoma cells, in good agreement with AKT pathway